IOVANCE BIOTHERAPEUTICS, INC. Stockholders Equity

Quick Answer

IOVANCE BIOTHERAPEUTICS, INC. reported Stockholders Equity of $698.58 million for the year ending 2025.

  • IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -1.7% in Stockholders Equity from 2024 to 2025.
  • This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2013: -$2.77 million | Q3 2013: -$3.34 million | Q1 2014: $16.81 million | Q2 2014: $17.38 million | Q3 2014: $16.16 million | Q1 2015: $111.63 million | Q2 2015: $112.87 million | Q3 2015: $109.37 million | Q1 2016: $98.94 million | Q2 2016: $188.94 million | Q3 2016: $179.13 million | Q1 2017: $149.89 million | Q2 2017: $129.15 million | Q3 2017: $165.44 million | Q1 2018: $292.56 million | Q2 2018: $270.57 million | Q3 2018: $254.16 million | Q1 2019: $434.93 million | Q2 2019: $397.42 million | Q3 2019: $355.06 million | Q1 2020: $243.31 million | Q2 2020: $758.31 million | Q3 2020: $711.84 million | Q1 2021: $647.43 million | Q2 2021: $744.41 million | Q3 2021: $698.33 million | Q1 2022: $551.99 million | Q2 2022: $472.69 million | Q3 2022: $393.74 million | Q1 2023: $666.88 million | Q2 2023: $578.57 million | Q3 2023: $674.01 million | Q1 2024: $680.02 million | Q2 2024: $768.54 million | Q3 2024: $773.46 million | Q1 2025: $767.87 million | Q2 2025: $698.49 million | Q3 2025: $702.29 million.
  • Over the full 14 years of available data (2012 to 2025), IOVANCE BIOTHERAPEUTICS, INC.'s Stockholders Equity has grown by 6,271.8%.
  • Historical annual values: Fiscal year 2025: $698.58 million | Fiscal year 2024: $710.41 million | Fiscal year 2023: $584.61 million | Fiscal year 2022: $499.64 million | Fiscal year 2021: $621.66 million | Fiscal year 2020: $656.50 million | Fiscal year 2019: $298.97 million | Fiscal year 2018: $466.19 million | Fiscal year 2017: $145.48 million | Fiscal year 2016: $166.92 million | Fiscal year 2015: $104.02 million | Fiscal year 2014: $44.85 million | Fiscal year 2013: $17.60 million | Fiscal year 2012: -$11.32 million.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: